Medicare drug pricing proposal not true negotiation, pharma group says

(By Rylee Wilson for Becker’s Hospital Review)

Pharmaceutical Research and Manufacturers of America says CMS’ guidance for Medicare drug price negotiation disadvantages manufacturers and will hurt innovation. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org